MoonLake Immunotherapeutics Class A Ordinary Shares (NASDAQ:MLTX)

Home >> Stock >> MoonLake Immunotherapeutics Class A Ordinary Shares >> Metrics

MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON....

+See More

Blog+More

Macro economic innovations and asset alphas show significant mutual causation.

Olivia London

2023-12-03 11:33:00 Sunday ET

Macro economic innovations and asset alphas show significant mutual causation.

Macro innovations and asset alphas show significant mutual causation. April 2023   This brief article draws from the recent research publicati

+See More

St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal.

Charlene Vos

2019-06-09 11:29:00 Sunday ET

St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal.

St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal. Bullard ind

+See More

European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to low inflation.

Peter Prince

2019-04-11 07:35:00 Thursday ET

European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to low inflation.

European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to key delays in inflation conver

+See More

Our proprietary alpha investment model outperforms most stock market indexes from 2017 to 2025.

James Campbell

2025-02-02 11:28:00 Sunday ET

Our proprietary alpha investment model outperforms most stock market indexes from 2017 to 2025.

Our proprietary alpha investment model outperforms most stock market indexes from 2017 to 2025. Our proprietary alpha investment model outperforms the ma

+See More

Carl Icahn mulls over steps to shake up the board of SandRidge Energy after it adopts a counter poison pill.

Jacob Miramar

2017-11-29 07:42:00 Wednesday ET

Carl Icahn mulls over steps to shake up the board of SandRidge Energy after it adopts a counter poison pill.

The octogenarian billionaire and activist investor Carl Icahn mulls over steps to shake up the board of SandRidge Energy after the oil-and-gas company adopt

+See More

Federal Reserve raises the interest rate again in mid-2018 in response to 2% inflation and wage growth.

John Fourier

2018-07-09 09:39:00 Monday ET

Federal Reserve raises the interest rate again in mid-2018 in response to 2% inflation and wage growth.

The Federal Reserve raises the interest rate again in mid-2018 in response to 2% inflation and wage growth. The current neutral interest rate hike neither b

+See More